Sonendo, Inc. (NYSE:SONX – Get Rating) CEO Bjarne Bergheim bought 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 18th. The stock was purchased at an average price of $2.67 per share, for a total transaction of $32,040.00. Following the completion of the transaction, the chief executive officer now directly owns 891,349 shares of the company’s stock, valued at approximately $2,379,901.83. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Bjarne Bergheim also recently made the following trade(s):
- On Monday, May 16th, Bjarne Bergheim bought 30,000 shares of Sonendo stock. The stock was purchased at an average price of $2.95 per share, for a total transaction of $88,500.00.
- On Friday, May 13th, Bjarne Bergheim sold 4,101 shares of Sonendo stock. The stock was sold at an average price of $2.78, for a total value of $11,400.78.
Shares of NYSE SONX opened at $2.94 on Friday. The business’s 50 day moving average is $3.54 and its two-hundred day moving average is $5.92. Sonendo, Inc. has a 1-year low of $2.50 and a 1-year high of $12.24. The company has a debt-to-equity ratio of 0.46, a current ratio of 6.86 and a quick ratio of 6.02.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. General Atlantic L.P. bought a new position in Sonendo in the fourth quarter worth approximately $18,822,000. Essex Woodlands Management Inc. bought a new position in Sonendo in the fourth quarter worth approximately $11,477,000. Skandinaviska Enskilda Banken AB publ bought a new position in Sonendo in the fourth quarter worth approximately $4,796,000. Perceptive Advisors LLC bought a new position in Sonendo in the fourth quarter worth approximately $3,851,000. Finally, Yu Fan bought a new position in Sonendo in the fourth quarter worth approximately $3,156,000. 80.42% of the stock is currently owned by hedge funds and other institutional investors.
A number of research firms recently commented on SONX. Zacks Investment Research downgraded Sonendo from a “hold” rating to a “sell” rating in a research report on Saturday, May 14th. Morgan Stanley began coverage on Sonendo in a research note on Monday, January 31st. They set an “equal weight” rating and a $6.90 price objective on the stock. Piper Sandler reduced their price objective on Sonendo from $12.00 to $7.00 in a research note on Wednesday, May 11th. Finally, The Goldman Sachs Group reduced their price objective on Sonendo from $30.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, March 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. According to MarketBeat, Sonendo presently has a consensus rating of “Buy” and an average target price of $10.32.
Sonendo Company Profile (Get Rating)
Sonendo, Inc, a commercial-stage medical technology company, develops, manufactures, and commercializes devices for root canal therapy in the United States and Canada. It provides GentleWave, a tooth decay treatment device for cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure.
- Get a free copy of the StockNews.com research report on Sonendo (SONX)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Will John Deere’s Earnings Help to Calm the Markets?
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Sonendo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonendo and related companies with MarketBeat.com's FREE daily email newsletter.